Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.
BC Women's Centre for Pelvic Pain and Endometriosis, F2 - 4500 Oak Street, Vancouver, British Columbia, V6H3N1, Canada.
Reprod Sci. 2021 Oct;28(10):2743-2757. doi: 10.1007/s43032-020-00451-9. Epub 2021 Jan 19.
In this review, we provide a survey and appraisal of research into somatic genomic events in endometriosis. Methodologies have evolved from conventional cytogenetics to next-generation sequencing, with findings ranging from chromosome imbalances to recurrent somatic cancer driver mutations. Somatic cancer driver mutations have been described in a range of endometriosis lesions, dominated by recurrent mutations in KRAS and PIK3CA as well as loss of PTEN and BAF250a (ARID1A). These somatic events appear to be largely restricted to the endometriosis glandular epithelium. Somatic mutations, particularly PTEN loss, have also been observed in eutopic (uterine) endometrium, although at lower mutant allele frequencies compared with ectopic lesions. Systematic studies of the potential clinical phenotype of these somatic genomic events have yet to be performed. Thus, we propose a framework to investigate the potential clinical phenotype associated with somatic genomic events in endometriosis. Technical requirements include pathology review of histological endometriosis, microdissection for tissue enrichment, orthogonal validation of whole genome/exome sequencing, and a germline sample for confirmation of somatic origin. Clinical requirements include annotation of surgical findings; patient demographics; cross-sectional and prospective data on pain and fertility; consideration of sampling multiple lesions in each patient, mutant allele frequency, and somatic events in the eutopic endometrium; and confirmation of any associations with mechanistic studies. Given the multifactorial nature of endometriosis-associated symptoms, it is likely that somatic events have small (or at most, moderate) effect sizes, and thus careful consideration will have to be given to future study design.
在这篇综述中,我们对子宫内膜异位症中的体基因组事件研究进行了调查和评估。研究方法已经从传统的细胞遗传学发展到下一代测序,研究结果从染色体失衡到复发性体细胞癌驱动突变不等。在一系列子宫内膜异位症病变中,已经描述了体细胞癌驱动突变,主要是 KRAS 和 PIK3CA 的复发性突变以及 PTEN 和 BAF250a(ARID1A)的缺失。这些体细胞事件似乎主要局限于子宫内膜异位症的腺体上皮。体细胞突变,特别是 PTEN 缺失,也在在位(子宫)子宫内膜中观察到,尽管与异位病变相比,突变等位基因频率较低。这些体细胞基因组事件的潜在临床表型的系统研究尚未进行。因此,我们提出了一个研究子宫内膜异位症中体细胞基因组事件相关潜在临床表型的框架。技术要求包括对组织学子宫内膜异位症进行病理检查、组织富集的显微解剖、全基因组/外显子测序的正交验证以及用于确认体细胞起源的种系样本。临床要求包括手术发现的注释;患者人口统计学;疼痛和生育力的横断面和前瞻性数据;考虑在每个患者中对多个病变进行采样、突变等位基因频率以及在位子宫内膜中的体细胞事件;并与机制研究进行确认。鉴于与子宫内膜异位症相关症状的多因素性质,体细胞事件可能具有较小(或最多为中度)的效应大小,因此必须仔细考虑未来的研究设计。